Skip to main content

A phase 1 study of CB-010, a CRISPR-edited allogeneic CAR-T targeting CD19, in patients with B-cell NHL


Caribou Biosciences


TAP Partner

Project Term: February 28, 2021 - TBD

In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma." CB-010, Caribou’s lead allogeneic CAR-T cell program, targets CD19 and is being evaluated in a Phase 1 clinical trial for patients with relapsed/refractory B cell non-Hodgkin lymphoma. It is the first clinical-stage allogeneic CAR-T cell therapy in which PD-1 was genetically disrupted in the CAR-T genome. The goal of the PD-1 knockout is to boost the persistence of CAR-T cell antitumor activity, which is believed to have the potential to reduce CB-010 exhaustion and potentially confer a better therapeutic index compared to other allogeneic CAR-T cells. CB-010 is the first allogeneic CAR-T cell therapy with a PD-1 knockout in clinical studies, and it is being evaluated in the ongoing, open-label, multicenter Phase 1 ANTLER clinical trial in the United States in adults with relapsed or refractory B cell non-Hodgkin lymphoma. 

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects